3D Biotek, LLC

3dbiotek.com

3D Biotek, LLC is a high tech biomedical engineering company located in the state of New Jersey, USA. Using its Precision 3D Micro-fabrication Technology and Advanced Bio-manufacturing Technology, 3D Biotek is a leader and the industry's only dedicated driving force in the research and development of novel 3-dimensional cell culture devices for stem cell/tissue engineering, drug discovery and broad cell biology applications.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

CAJAL NEUROSCIENCE LAUNCHES WITH $96 MILLION TO TRANSFORM TARGET AND DRUG DISCOVERY IN NEURODEGENERATION

Cajal Neuroscience | November 30, 2022

news image

Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, launched today with the completion of a $96 million Series A financing. Cajal is uniquely focused on the mechanistic, spatial and temporal complexity of neurodegeneration, integrating deep expertise in neuroscience, neuroanatomy and computational biology with state-of-the-art technologies for high-throughput function...

Read More

INRAE, EVOLUGATE ENTER OPTION LICENSE AGREEMENT TO ADVANCE PROBIOTICS TO MANAGE HUMAN CHOLESTEROL

Evolugate | May 28, 2020

news image

INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...

Read More

Industrial Impact, Medical

HITGEN ANNOUNCES RESEARCH AGREEMENT WITH NITRASE THERAPEUTICS FOCUSED ON DNA-ENCODED LIBRARY BASED DRUG DISCOVERY

HitGen Inc. | December 12, 2022

news image

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases. Nitrases have been implicated in numerous devastating diseases, including Parkinson's, cancer, respiratory diseases, fibrosis ...

Read More

Cell and Gene Therapy

MATICA BIO ANNOUNCES JOINT RESEARCH AGREEMENT WITH SARTORIUS FOR THE DEVELOPMENT OF ADVANCED VIRAL VECTOR MANUFACTURING TECHNOLOGY

Matica Biotechnology, Inc. | October 19, 2021

news image

Matica Biotechnology, Inc, (Matica Bio) a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will work on a number of studies together to streamline and optimize PAT technologies, automation software, and single-use platforms offe...

Read More
news image

Medical

CAJAL NEUROSCIENCE LAUNCHES WITH $96 MILLION TO TRANSFORM TARGET AND DRUG DISCOVERY IN NEURODEGENERATION

Cajal Neuroscience | November 30, 2022

Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, launched today with the completion of a $96 million Series A financing. Cajal is uniquely focused on the mechanistic, spatial and temporal complexity of neurodegeneration, integrating deep expertise in neuroscience, neuroanatomy and computational biology with state-of-the-art technologies for high-throughput function...

Read More
news image

INRAE, EVOLUGATE ENTER OPTION LICENSE AGREEMENT TO ADVANCE PROBIOTICS TO MANAGE HUMAN CHOLESTEROL

Evolugate | May 28, 2020

INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...

Read More
news image

Industrial Impact, Medical

HITGEN ANNOUNCES RESEARCH AGREEMENT WITH NITRASE THERAPEUTICS FOCUSED ON DNA-ENCODED LIBRARY BASED DRUG DISCOVERY

HitGen Inc. | December 12, 2022

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases. Nitrases have been implicated in numerous devastating diseases, including Parkinson's, cancer, respiratory diseases, fibrosis ...

Read More
news image

Cell and Gene Therapy

MATICA BIO ANNOUNCES JOINT RESEARCH AGREEMENT WITH SARTORIUS FOR THE DEVELOPMENT OF ADVANCED VIRAL VECTOR MANUFACTURING TECHNOLOGY

Matica Biotechnology, Inc. | October 19, 2021

Matica Biotechnology, Inc, (Matica Bio) a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will work on a number of studies together to streamline and optimize PAT technologies, automation software, and single-use platforms offe...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us